This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Consequently, the Royal College of General Practitioners and the Royal College of Physicians ended their corporate partnerships as it would be in breach of their ethical guidance. The Novo UK General Manager, Pinder Sahota, chose to resign as President of the ABPI prior to the suspension. In August 2023, one of the first lawsuits was filed alleging that Novo's Ozempic and Eli Lilly's Mounjaro (tirzepatide) caused severe gastrointestinal side effects, including gastroparesis. The lawsuit was brought on behalf of Jaclyn Bjorklund, a Louisiana woman represented by Morgan & Morgan, who alleged that she suffered persistent vomiting and other serious injuries after using the drugs and that the manufacturers failed to adequately warn patients and physicians about the risks. In September 2023, the law firm Motley Rice filed a lawsuit on behalf of a Pennsylvania woman who had been taking weight-loss drug Wegovy. The lawsuit alleges that the plaintiff experienced severe stomach cramping, vomiting, and nausea requiring hospitalization, and that Novo failed to adequately warn patients about the risk of gastroparesis. In February 2024, the United States Judicial Panel on Multidistrict Litigation ordered that 55 lawsuits pending in federal courts be consolidated into a multidistrict litigation. The majority of the cases were against Novo, but some were brought against Eli Lilly. As of August 2024 there were 235 active Ozempic lawsuits.
=== Initiation of production in fetuses === Thyrotropin-releasing hormone (TRH) is released from hypothalamus by 6–8 gestational weeks, and thyroid-stimulating hormone (TSH) secretion from the fetal pituitary gland is evident by 12 gestational weeks; fetal production of thyroxine (T4) reaches a clinically significant level at 18–20 weeks. Fetal triiodothyronine (T3) remains low (less than 15 ng/dL) until 30 weeks of gestation, and increases to 50 ng/dL at term. Fetal self-sufficiency of thyroid hormones protects the fetus against, for example, neurodevelopmental abnormalities caused by maternal hypothyroidism.
=== Origin of antiviral resistance === The genetic makeup of viruses is constantly changing, which can cause a virus to become resistant to currently available treatments. Viruses can become resistant through spontaneous or intermittent mechanisms throughout the course of an antiviral treatment. Immunocompromised patients, more often than immunocompetent patients, hospitalized with pneumonia are at the highest risk of developing oseltamivir resistance during treatment. Subsequent to exposure to someone else with the flu, those who received oseltamivir for "post-exposure prophylaxis" are also at higher risk of resistance. The mechanisms for antiviral resistance development depend on the type of virus in question. RNA viruses have high error rates during genome replication because RNA polymerases lack proofreading activity. RNA viruses also have small genome sizes that are typically less than 30 kb, which allow them to sustain a high frequency of mutations. The likelihood of mutations is exacerbated by the speed with which viruses reproduce, which provides more opportunities for mutations to occur in successive replications. Billions of viruses are produced every day during the course of an infection, with each replication giving another chance for mutations that encode for resistance to occur. Multiple strains of one virus can be present in the body at one time, and some of these strains may contain mutations that cause antiviral resistance.
Sources: en.wikipedia.org
== Bibliography == Winstein, Merryl (2017). Successful Cheesemaking™, Step-by-Step Directions and Photos for Making Nearly Every Type of Cheese, (670pp, 800 photos). St. Louis, Missouri: Smooth Stone Press. ISBN 978-0998595955. Robinson, R.K.; Wilbey, R.A. (1998). Cheesemaking practice (3rd ed.). Dordrecht: Kluwer Academic. Banks, J (1998). Cheese (2nd ed.). Early, R. The technology of dairy products. London: Chapman and Hall. Jenkins, Steven (1996). Cheese Primer. New York: Workman Publishing. Tannahill, Reay (2008). Food in History. New York: Three Rivers Press.
Andrew went into business with his father in the United States in 1973, opening their first Panda Inn restaurant in Pasadena, California. At the beginning, business was lacking to the degree that Andrew had to offer special deals and freebies so that customers would dine at Panda Inn. In 1982, Peggy joined Andrew in the restaurant business. While operating Panda Inn, Andrew became acquainted with then-UCLA head football coach Terry Donahue, as well as Terry's brother Dan, who happened to be in the real estate business. It was because of this connection that in 1983, Donahue Schriber Real Estate, the manager of the Glendale Galleria, invited the Cherngs to develop a fast-food version of Panda Inn for the Galleria's food court, and Panda Express was launched that October. A second location was opened two years later at the Westside Pavilion in 1985. The chain has steadily expanded across the United States since then. Chef Andy Kao claims to have developed the original Chinese-American orange chicken recipe at a Panda Express in Hawaii in 1987.At first, Panda Express restaurants were found solely in food courts in major shopping malls. During the late 1980s and early 1990s, the Cherngs began experimenting with supermarket-based branches, through a deal with Vons, and then stand-alone restaurant locations. In 1997, the company opened its first stand-alone, drive-through restaurant, in Hesperia, California. Today less than 2% of its restaurants are in malls.
The DNA synthesizer played a critical role in the identification of many important genes and in the development of the polymerase chain reaction (PCR), the critical technique used to amplify segments of DNA a million-fold. The first commercial automated peptide synthesizer, sometimes referred to as a protein synthesizer, was developed by Hood and Stephen B. H. Kent, a senior research associate at Caltech from 1983 to 1989. The automated, programmable peptide synthesizer had previously been invented and developed by Bruce Merrifield and colleagues at Rockefeller University, and Merrifield received the Novel Prize for this invention. The peptide synthesizer assembles long peptides and short proteins from amino acid subunits, in quantities sufficient for subsequent analysis of their structure and function. The commercially available instrument from Applied Biosystems led to a number of significant results, including the synthesis of HIV-1 protease in a collaboration between Kent and Merck and the analysis of its crystalline structure. Based on this research, Merck developed an important antiprotease drug for the treatment of AIDS. Kent carried out a number of important synthesis and structure-function studies in Hood's lab at Caltech. Among the notable of the inventions from Hood's lab was the automated DNA sequencer. It made possible high-speed sequencing of the structure of DNA, including the human genome. It automated many of the tasks that researchers had previously done by hand. Researchers Jane Z. Sanders and Lloyd M.
Characteristically, next to the lining epithelium, there is an intense lymphocytic infiltrate. Superimposed infection may convert these lesions into abscess cavities, and rarely, give rise to cancers. Another disorder is that of thyroid dysgenesis which can result in various presentations of one or more misplaced accessory thyroid glands. These can be asymptomatic.
Sources: en.wikipedia.org
=== Signs of injury === Stretching for too long or too much can give way to an injury. For most activities, the normal range of motion is more than adequate. Any sudden movements or going too fast can cause a muscle to tighten. This leads to extreme pain and the performer should let the muscle relax by resting.
=== Older adults === Aging is associated with sarcopenia, a decrease in muscle mass and strength. Resistance training can mitigate this effect, and even the oldest old (those above age 85) can increase their muscle mass with a resistance training program, although to a lesser degree than younger individuals. With more strength older adults have better health, better quality of life, better physical function and fewer falls. Resistance training can improve physical functioning in older people, including the performance of activities of daily living. Resistance training programs are safe for older adults, can be adapted for mobility and disability limitations, and may be used in assisted living settings. Resistance training at lower intensities such as 45% of 1RM can still result in increased muscular strength.
=== Judicial === The Rhodesian High Court's nine Appellate and General Division judges initially neither rejected UDI nor openly supported it. The Chief Justice Sir Hugh Beadle, of the Appellate Division, announced simply that the judges would go on carrying out their duties "according to the law". This originally noncommittal stance evolved over time, largely pivoting around legal cases argued at the High Court in Salisbury between 1966 and 1968. The first of these, Madzimbamuto v. Lardner-Burke N. O. and Others, concerned Daniel Madzimbamuto, a black Rhodesian who was detained without trial by the Rhodesian government on 6 November 1965, the day after the declaration of a state of emergency and five days before UDI, on the grounds that he might pose a danger to the public. Desmond Lardner-Burke, the Rhodesian Minister of Justice and Law and Order, prolonged the state of emergency in February 1966, prompting Madzimbamuto's wife to appeal for his release, arguing that since the United Kingdom had declared UDI illegal and outlawed the Rhodesian government with the Southern Rhodesia Act 1965, the state of emergency (and, by extension, Madzimbamuto's imprisonment) had no legal basis. The General Division of the Rhodesian High Court ruled on 9 September 1966 that legal sovereignty lay with the British government, but that to "avoid chaos and a vacuum in the law" the Rhodesian government should be considered to be in control of law and order to the same extent as before UDI.
== Neuron-intrinsic changes == Immediately following injury, neurons undergo a large number of transcriptional and proteomic changes which switch the cell from a mature, synaptically active neuron to a synaptically silent, growth state. This process is dependent on new transcription, as blocking the ability of cells to transcribe new mRNA severely impairs regeneration. A number of signaling pathways have been shown to be turned on by axon injury and help to enable long distance regeneration including BMP, TGFβ, and MAPKs. Similarly, a growing number of transcription factors also boost the regenerative capacity of peripheral neurons including ASCL1, ATF3, CREB1, HIF1α, JUN, KLF6, KLF7, MYC, SMAD1, SMAD2, SMAD3, SOX11, SRF, STAT3, TP53, and XBP1. Several of these can also boost the regenerative capacity of CNS neurons, making them potential therapeutic targets for treating spinal cord injury and stroke.
== Galleries and gardens == The birthplace of the MNHN and a large part of its modern collections are found in five galleries in the Jardin des Plantes. These are the Gallery of Evolution; the Gallery of Mineralogy and Geology; the Gallery of Botany; the Gallery of Palaeontology and Comparative Anatomy, and the Laboratory of Entomology.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.